Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Drug Design Strategy May Fight Cancer More Effectively with Fewer Side Effects

By BiotechDaily International staff writers
Posted on 27 Jun 2012
A new approach to drug design has the potential to help identify future drugs to combat cancer and other diseases that will be more effective and have fewer side effects.

The design application was engineered by scientists from the University of California, San Francisco (UCSF; USA) and Mt. Sinai Medical Center (New York, NY, USA). Instead of looking for find magic bullets--chemicals that specifically attack one gene or protein involved in one specific part of a disease process--the new approach is searching for “magic shotguns” by sifting through the known field of chemicals to find the few special molecules that broadly disrupt the whole diseases process.

“We’ve always been looking for magic bullets,” said Kevan Shokat, PhD, chair of the department of cellular and molecular pharmacology at UCSF. “This is a magic shotgun--it doesn’t inhibit one target but a set of targets--and that gives us a much, much better ability to stop the cancer without causing as many side effects.”

Described in the June 7, 2012, issue of the journal Nature, the magic shotgun approach has already provided two potential drugs, called AD80 and AD81, which in fruit flies were more effective and less toxic than the drug vandetanib, approved by the US Food and Drug Administration (FDA) last year for the treatment of a certain type of thyroid cancer.

Drug design essentially entails disruption: in any disorder, there are many molecular interactions and other mechanisms that take place within specific tissues, and in the widest sense, most drugs are simply chemicals that interfere with the proteins and genes involved in those processes. The better a drug disrupts key parts of a disease process, the more effective it is.

The toxicity of a drug, however, refers to how it also disrupts other parts of the body’s system. Drugs always fall short of perfection in this sense, and all pharmaceuticals have some level of toxicity due to unwanted interactions the drugs have with other molecules in the body.

Scientists utilize the therapeutic index (the ratio of effective dose to toxic dose) as a way of defining how severe the side effects of a given drug would be. Many of the safest drugs on the market have therapeutic indexes that are 20 or higher--meaning that a person would have to take 20 times the prescribed dose to suffer severe side effects.

Many cancer drugs, on the other hand, have a therapeutic index of 1. In other words, the amount of the drug you need to take to treat the cancer is the exact amount that causes severe side effects. The difficulty, according to Dr. Shokat, is that cancer drug targets are so similar to normal human proteins that the drugs have widespread effects felt far outside the tumor.

While suffering the side effects of drugs is a reality that many people with cancer face, finding ways of minimizing this toxicity is a big aim pharmaceutical companies would like to resolve. Dr. Shokat and his colleagues believe the shotgun approach is one way to achieve this. The view that the best drugs are the most selective could be mistaken, Dr. Shokat noted, and for cancer, a magic shotgun may be more effective than a magic bullet.

Studying fruit flies, the investigators found a way to screen compounds to find the few that best disrupt an entire network of interacting genes and proteins. Instead of assessing a compound according to how well it suppresses a specific target, they deemed as best the compounds that inhibited not only that specific target but disrupted other areas of the network while not interacting with other genes and proteins that would cause toxic side effects.

Related Links:

University of California, San Francisco
Mt. Sinai Medical Center



RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.